Table of Contents

company-logo

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.

Statera Biopharma Dividend Announcement

• Statera Biopharma does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Statera Biopharma dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Statera Biopharma Dividend History

Statera Biopharma Dividend Yield

Statera Biopharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Statera Biopharma stock? Use our calculator to estimate your expected dividend yield:

Statera Biopharma Financial Ratios

P/E ratio-0.00
PEG ratio-0.00
P/B ratio-0.00
ROE6677.48%
Payout ratio0.00%
Current ratio0.37
Quick ratio0.37
Cash Ratio0.16

Statera Biopharma Dividend FAQ

Does Statera Biopharma stock pay dividends?
Statera Biopharma does not currently pay dividends to its shareholders.
Has Statera Biopharma ever paid a dividend?
No, Statera Biopharma has no a history of paying dividends to its shareholders. Statera Biopharma is not known for its dividend payments.
Why doesn't Statera Biopharma pay dividends?
There are several potential reasons why Statera Biopharma would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Statera Biopharma ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Statera Biopharma has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Statera Biopharma a dividend aristocrat?
Statera Biopharma is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Statera Biopharma a dividend king?
Statera Biopharma is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Statera Biopharma a dividend stock?
No, Statera Biopharma is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Statera Biopharma stocks?
To buy Statera Biopharma you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Statera Biopharma stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.